Matt Henriksen

But, you know, we also talked about the type one and the type two market.

You know, we talked about, you know, roughly the same size, but different

access points for those patients.

The other interesting thing that I've taken from this is that while technically the islet doesn't have a label for the type 2, during your earning calls, you're highlighting how these primary care physicians are still prescribing it to those patients.

And you're mentioning a significant amount of patients, almost up to 30%, if I remember correctly, that of your new patients are actually type 2.

So...

Well, one winded way of asking about how is those, you know, how are those approaches different for the type one patients and the type two patients?

Yeah.

And you know, it's interesting too, because I mean, I believe you guys are considering a type two label, um,

Yeah, I can see the benefits in one way or the other.

On one hand, you're already reaching out to the, not you, but the doctors are already reaching out to those type two patients.

So you're kind of already getting that growth.

But if you have an official label, I could see that growth even growing even exponentially more.

But I guess one of the questions I have is, do you need a separate clinical trial to show that benefit for the type two patients?

Yeah.

then hey if that if we're talking about that you know being proved wrong is that growth accelerates further i mean that's a good reason i'm happy to be proved wrong in that way yeah um but you know let's talk about some of the other developments then because you know um you know we've talked a lot about the eyelet for the first you know 25 30 minutes here um but

We also were talking earlier about how there's different form factors and there's a traditional pump, but there's also the on-the-body wear.

What are your developments for an on-the-body wear for those patients that prefer that kind of more discreet fit?

Now, is that one of those things, because we talked earlier about, you know, taking a few days for kind of the algorithm to learn the specific patient.

Is that reusable portion able to kind of keep that data more and be able to, you know, benefit from that, you know, machine learning advantage?